MX2023006148A - Polipeptidos que eligen como objetivo a dr4 y/o dr5 y composiciones y metodos relacionados. - Google Patents

Polipeptidos que eligen como objetivo a dr4 y/o dr5 y composiciones y metodos relacionados.

Info

Publication number
MX2023006148A
MX2023006148A MX2023006148A MX2023006148A MX2023006148A MX 2023006148 A MX2023006148 A MX 2023006148A MX 2023006148 A MX2023006148 A MX 2023006148A MX 2023006148 A MX2023006148 A MX 2023006148A MX 2023006148 A MX2023006148 A MX 2023006148A
Authority
MX
Mexico
Prior art keywords
methods
related compositions
nanocage
polypeptides targeting
fusion protein
Prior art date
Application number
MX2023006148A
Other languages
English (en)
Spanish (es)
Inventor
Jean- Philippe Julien
Diez Edurne Rujas
Original Assignee
Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital For Sick Children filed Critical Hospital For Sick Children
Publication of MX2023006148A publication Critical patent/MX2023006148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023006148A 2020-11-25 2021-11-25 Polipeptidos que eligen como objetivo a dr4 y/o dr5 y composiciones y metodos relacionados. MX2023006148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063118306P 2020-11-25 2020-11-25
PCT/CA2021/051690 WO2022109743A1 (en) 2020-11-25 2021-11-25 Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2023006148A true MX2023006148A (es) 2023-08-07

Family

ID=81753696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006148A MX2023006148A (es) 2020-11-25 2021-11-25 Polipeptidos que eligen como objetivo a dr4 y/o dr5 y composiciones y metodos relacionados.

Country Status (9)

Country Link
US (1) US20240182544A1 (https=)
EP (1) EP4251654A4 (https=)
JP (1) JP2023550191A (https=)
KR (1) KR20230116833A (https=)
CN (1) CN116917339A (https=)
AU (1) AU2021386892A1 (https=)
CA (1) CA3202378A1 (https=)
MX (1) MX2023006148A (https=)
WO (1) WO2022109743A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240101550A9 (ko) * 2021-09-13 2025-12-10 더 호스피탈 포 식 칠드런 암 치료용 dr5-표적화 다중체
KR20250135167A (ko) * 2022-09-11 2025-09-12 래디언트 바이오테라퓨틱스 인크. 다중체를 사용하는 화학요법-내성 종양의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195626B (zh) * 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
JP2022529512A (ja) * 2019-04-25 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗体で修飾した自己集合するタンパク質ナノケージ（ｓａｐｎａ）及びその部分

Also Published As

Publication number Publication date
CN116917339A (zh) 2023-10-20
CA3202378A1 (en) 2022-06-02
AU2021386892A1 (en) 2023-06-22
JP2023550191A (ja) 2023-11-30
AU2021386892A9 (en) 2024-08-08
EP4251654A1 (en) 2023-10-04
US20240182544A1 (en) 2024-06-06
WO2022109743A1 (en) 2022-06-02
KR20230116833A (ko) 2023-08-04
EP4251654A4 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
SA520420526B1 (ar) Caix، بروتينات ربط متعددة النوعية تستهدف أوano1،أو ميسوثيلين، أوtrop2،أوcea، أو كلاودين-18.2
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
WO2022082073A3 (en) Compositions and methods for muc18 targeting
PH12019502561A1 (en) Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
ZA202104287B (en) Novel fusion proteins specific for cd137 and gpc3
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
WO2022256498A9 (en) Msln targeting trispecific proteins and methods of use
MX2023006148A (es) Polipeptidos que eligen como objetivo a dr4 y/o dr5 y composiciones y metodos relacionados.
MX2020006822A (es) Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa.
HRP20251352T1 (hr) Humanizirani fragment ant-vegf fab protutijela i njegova upotreba
WO2018191363A8 (en) Targeted combination therapy
WO2019118512A3 (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
BR112022005044A2 (pt) Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
EP4610275A3 (en) Anti-pd-1 antibodies and fusion proteins
WO2021003050A3 (en) Cd38-binding agents and uses thereof